BIO
Recipharm Advanced Bio is advancing RNA therapeutics through hollow fiber cartridge and flat sheet cassette systems for TFF
Recipharm Advanced Bio is redefining how RNA vaccines and therapeutics are manufactured by optimizing membrane selection for the tangential flow filtration step. By offering both hollow fiber cartridges and flat sheet cassette systems, the development models stay flexible for ionizable lipid libraries, increased yield requirements, and scalability.
- Lipid nanoparticles (LNPs) are the leading non-viral gene delivery platform in gene therapy, owing to their lower manufacturing costs compared with adeno-associated viruses (AAVs), reduced immunogenicity relative to viral vectors, and high nucleic acid cargo capacity.
- The flexibility of LNP and its tested proof of concept during the COVID pandemic have made the LNP delivery system the golden platform for both vaccine application and gene editing.
- Moving forward with the knowledge accumulated during the pandemic and the resources that were invested into non-viral gene delivery, we still have a lot to learn and uncover with how the drug product (DP) components can interfere with the API biological activity.